UK Medical Cannabis Strains for Fibromyalgia: Full Terpene Breakdown

A University of Arizona paper, published online in December 2024, tested four cannabis-derived terpenes in mice. The researchers used two laboratory models: a small paw incision to model post-operative pain, and a drug-induced state intended to reproduce some features of fibromyalgia. All four terpenes made the mice less sensitive to pressure, with geraniol producing the strongest overall effect. Unlike THC, these compounds are not associated with THC-like psychoactive effects. A University of Arizona release resurfaced on ScienceDaily this month, prompting a simple question: if geraniol stood out in these experiments, can a UK patient actually find it?

The answer is yes, technically, once. Out of 449 flower listings in TheGreenAvenger’s Medicann formulary tracker, exactly one names geraniol among its reported terpenes. Whether it is actually available to order is a separate, faster-moving question, covered below.

The study

John Streicher’s lab at the University of Arizona College of Medicine tested geraniol, linalool, beta-caryophyllene and alpha-humulene. The paper describes “mouse models of post-operative pain and fibromyalgia”, which does not mean the mice literally had either condition.

For the post-operative model, the researchers made a small incision in a mouse’s paw. For the fibromyalgia model, they used reserpine, a drug treatment used in research to create heightened pain sensitivity resembling some features of fibromyalgia. After those models were established, each mouse received one terpene. The researchers then used calibrated filaments to test how much pressure the mice tolerated over the next three hours.

All four terpenes raised that pressure threshold. In plain English, the treated mice became less sensitive to pressure. Geraniol produced the largest overall change. The other terpenes also showed effects, but the exact order varied between the two models, so a neat one-to-four ranking would overstate what the paper shows.

The team also tested a possible biological pathway. When mice were given istradefylline, which blocks the adenosine A2a receptor, the terpene effect disappeared. That suggests this receptor was involved in the observed effect in these mice. It does not establish that the same mechanism, dose or result will apply in people.

This is preclinical research, not a human trial. It did not test people with fibromyalgia, compare geraniol with THC, or test any UK prescription product. This piece is about whether the market gives patients enough information to identify a compound that has drawn research interest, not about what anyone should take.

What’s actually on the market

TheGreenAvenger’s Medicann formulary is a patient-facing tracker built from MedBud product information. It records details including brand, cultivator, price, THC, CBD and, where supplied, terpene information. Of the 449 flower listings in the dataset used here, 338 report at least some terpene content. The remaining 111 are marked “Not Listed”.

That limitation is important. A terpene missing from a product listing is not proof that it was chemically absent from the flower. It may not have been tested for, may not have been included in the product information, or may simply not appear in the dataset. The figures below show what was reported on listings, not the true chemical prevalence of each terpene across the UK market.

Across those 449 listings:

Caryophyllene: 272 products (60.6%)
Linalool: 149 products (33.2%)
Humulene: 82 products (18.3%)
Geraniol: 1 product (0.2%)

That one geraniol-listed product is Chapel of Love, grown by Herdade Das Barrocas in Portugal and listed at 29% THC. On this dataset, it is the only flower carrying all four terpenes studied by the Arizona team. At the time of writing it was listed as out of stock on TheGreenAvenger’s tracker. Stock changes constantly, so check the MedBud link directly for the current position.

Twenty-four other products carry three of the four, caryophyllene, humulene and linalool, without geraniol. The full list:

UK flower products carrying three or more of the four studied terpenes
Strain	THC	Caryophyllene	Humulene	Linalool	Geraniol	Origin
Herdade Das Barrocas – Chapel of Love	29%	✓	✓	✓	✓	Portugal
Peace Naturals – Atomic Sour Grapefruit	30%	✓	✓	✓	–	Canada
Herdade Das Barrocas – Banana Sherbet	25%	✓	✓	✓	–	Portugal
Aurora Pedanios – Black Jelly	27%	✓	✓	✓	–	Canada
IPS – Blunicorn	26%	✓	✓	✓	–	South Africa
Superseed – Cake City	28%	✓	✓	✓	–	Canada
IPS – Cali Sunset	27%	✓	✓	✓	–	Denmark
Aurora Pedanios – Cosmic Cream	31%	✓	✓	✓	–	Canada
ANTG – El Jefe	26%	✓	✓	✓	–	Australia
Medicus – Fire Cookies	27%	✓	✓	✓	–	Canada
Medicus – Fire Cookies (SMALLS)	24%	✓	✓	✓	–	Canada
BC Green – Heavy Gas Hitter	30%	✓	✓	✓	–	Canada
Sundaze – Jet Fuel Pie	28%	✓	✓	✓	–	Canada
IPS – King’s Kush	24%	✓	✓	✓	–	North Macedonia
ANTG – Libras	10%	✓	✓	✓	–	Australia
Miracle Valley Canada – Miracle Alien Cookies	25%	✓	✓	✓	–	Canada
Curaleaf – Permanent Fumez	23%	✓	✓	✓	–	Australia
CannFX – Rainbow Pie	27%	✓	✓	✓	–	New Zealand
IPS – Strawberry Lemonade	21%	✓	✓	✓	–	North Macedonia
MUZO – Sudz	27%	✓	✓	✓	–	Canada
ANTG – Tangie Chem	23%	✓	✓	✓	–	Australia
Herdade Das Barrocas – Tigerz Eye	29%	✓	✓	✓	–	Portugal
Curaleaf – Wedding Pop Triangle	24%	✓	✓	✓	–	Portugal
Find – Wedding Pop Triangle(SMALLS)	22%	✓	✓	✓	–	Portugal
Cali-X – Zkittlez	24%	✓	✓	✓	–	Unknown

Source: TheGreenAvenger Medicann Formulary product data, accessed 28 June 2026. A tick means the terpene was named on the product listing. It does not show the concentration, and a dash does not prove the terpene was chemically absent. 111 of the 449 flower listings had no terpene information at all. Click a strain name to view its current listing, including current stock, on MedBud.

Not on the menu, even when it’s in the building

There is a separate, narrower issue. My own account with Medicann, a UK medical cannabis clinic, lets patients filter available products by terpene. The list of filter options is fixed.

Screenshot of the terpene filter dropdown inside a Medicann patient portal account, listing terpenes in alphabetical order: Bisabolol, Camphene, Caryophyllene, Eucalyptol, Germacrene, Guaiol, Humulene. There is no Geraniol entry between Eucalyptol and Germacrene, where it would alphabetically appear. — Medicann’s own terpene filter, screenshotted from a logged-in patient account on 28 June 2026. Eucalyptol, Germacrene, Guaiol and Humulene are all visible together in a single, unscrolled view, with nothing between Eucalyptol and Germacrene. Geraniol would sit alphabetically in that gap. It isn’t there.

This should not be read as evidence that geraniol is absent from the UK market. The tracker shows one listing that names it. What the screenshot shows is more limited: on at least one clinic platform, a patient browsing the available range cannot filter for geraniol because it is not offered as a search option.

The screenshot cannot tell us why that option is missing. It may reflect the clinic’s chosen list of tags, the way its product data is supplied, or the current range. But the practical effect is clear: a patient cannot use that filter to look for geraniol. Alongside the incomplete listing data above, it shows how difficult it is to turn a research finding into a straightforward product search.

A non-intoxicating option, not a replacement for THC

The “without the high” angle is understandable, but it is easy to overread. A compound without THC-like psychoactive effects could be useful for patients who prefer to avoid impairment. That does not make it a universal upgrade on THC-containing medicine.

This study did not compare geraniol with THC, cannabis flower or any current prescription product. It cannot tell us whether geraniol works as well as THC in people, whether the two compounds work better together, what dose would matter, or which patients would prefer one approach over another. It identifies a research lead, not a replacement for existing treatment.

What this doesn’t show

This is not evidence that geraniol is absent from UK cannabis. It shows that only one of 449 flower listings in this dataset names it. Because 111 listings report no terpene information at all, the 0.2% figure means “reported on 0.2% of listings”, not “chemically present in 0.2% of UK flower”.

It is also not a reason to choose a product on the strength of a mouse study. The Arizona work is preclinical. The product data does not give a concentration for any of the four terpenes, so a listing that names caryophyllene, linalool, humulene or geraniol could represent a trace amount or a much larger one. This dataset cannot distinguish between them.

The immediate problem is not simply that geraniol is hard to find. It is that patients and prescribers are not given a consistent, comparable picture of terpene content. They cannot reliably see whether a compound was tested for, how much of it is present, or whether a relevant product is actually available. That makes responsible, evidence-led product comparison far harder than it should be.